Literature DB >> 25419748

Hydroxychloroquine-induced fatal toxic epidermal necrolysis complicated by angioinvasive rhizopus.

Michael C Cameron, Andrew P Word, Arturo Dominguez1.   

Abstract

The majority of toxic epidermal necrolysis (TEN) cases are provoked by "high risk" medications (e.g. allopurinol, aromatic anticonvulsants, nevirapine, oxicam non-steroidal anti-inflammatory agents, and sulfonamides). TEN usually occurs 1 to 8 weeks after initial administration of the offending agent, but re-administration can evoke TEN within hours to days. Hydroxychloroquine has rarely been associated with TEN, with one case proving fatal. Herein, we report a case of hydroxychloroquine-induced fatal TEN complicated by angioinvasive Rhizopus. To our knowledge, this is the first case report of angioinvasive Rhizopus in a TEN patient. Initial misidentification of the offending agent causing TEN also serves as an important teaching point worth highlighting.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25419748

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  6 in total

1.  Hydroxychloroquine-Induced Erythema Multiforme.

Authors:  Nour Abou Assalie; Robert Durcan; Laura Durcan; Michelle A Petri
Journal:  J Clin Rheumatol       Date:  2017-03       Impact factor: 3.517

Review 2.  Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.

Authors:  David N Juurlink
Journal:  CMAJ       Date:  2020-04-08       Impact factor: 8.262

Review 3.  Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.

Authors:  Sergio Marin; Alba Martin Val; Maite Bosch Peligero; Cristina Rodríguez-Bernuz; Ariadna Pérez-Ricart; Laia Vilaró Jaques; Roger Paredes; Josep Roca; Carles Quiñones
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-21

Review 4.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

5.  Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.

Authors:  Can Chen; Kunming Pan; Bingjie Wu; Xiaoye Li; Zhangzhang Chen; Qing Xu; Xiaoyu Li; Qianzhou Lv
Journal:  Eur J Clin Pharmacol       Date:  2020-08-11       Impact factor: 2.953

6.  Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.

Authors:  Aslı Gelincik; Knut Brockow; Gülfem E Çelik; Inmaculada Doña; Cristobalina Mayorga; Antonino Romano; Özge Soyer; Marina Atanaskovic-Markovic; Annick Barbaud; Maria Jose Torres
Journal:  Allergy       Date:  2020-07-01       Impact factor: 14.710

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.